Through its world class research enterprise and dedicated clinicians, Memorial Sloan Kettering Cancer Center (MSK) is leading the way in the detection and treatment of kidney cancer. MSK doctors and scientists take a personalised approach using targeted diagnostic methods, genetic sequencing of tumours, and innovative, tailored treatments to fight each patient’s cancer.

Mazumdar Shaw Philanthropy’s gift enabled the establishment of the Mazumdar Shaw Translational Research Initiative in Kidney Cancer Research in 2022. It has empowered four multidisciplinary teams of highly specialised physicians and scientists to make impressive strides toward innovative treatments that improve patient outcomes. Additionally, MSK has formalised their research goals into an application for a Specialized Programs of Research Excellence grant, a prestigious award of US$5 million given by the National Cancer Institute. This grant requires researchers to prove additional sources of funding, which MSP’s gift has supported. If approved, the grant will be used to establish a comprehensive translational kidney cancer research programme that will lay the foundation for a kidney cancer centre at MSK.